Description Blinatumomab, marketed under the brand name BLINCYTO, It is an prescription medication that has been approved blinatumomab (Blincyto) on June 14, 2024 for the treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL) in adults and children one month and older. What is BLINCYTO (blinatumomab) ? BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with: B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Source Content From US FDA How to order approved “BLINCYTO (blinatumomab) for injection” Medicine? BLINCYTO (Blinatumomab) Injection is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing BLINCYTO and arranging delivery to your location, please get in touch with Mr. Rakesh at 91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
